Sukhmani Padda, MD

Sukhmani Padda, MD, an assistant professor of medicine at Stanford Cancer Institute, discusses the role of immunotherapy in patients with

-positive nonsmall cell lung cancer (NSCLC).

Immunotherapy has not been the biggest hit yet for this patient population, says Padda. However, it can play a role in a more selective patient population.

Immunotherapy should only be considered for these patients with

-mutant NSCLC after all targeted therapies have been tried, as well as a platinum doublet chemotherapy. However, even in patients with high PD-L1 expression, the response rates with immunotherapy have not been that high.

Videos

Sukhmani Padda, MD, discusses the role of immunotherapy in patients with <em>EGFR</em>-positive non&ndash;small cell lung cancer.

Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer

Sukhmani Padda, MD, assistant professor of medicine at Stanford University, discusses how third-generation EGFR tyrosine kinase inhibitors (TKIs) compare to the first- and second-generation TKIs.

Osimertinib (Tagrisso) is currently the only approved third-generation TKI, but this agent has dramatically changed the treatment landscape in lung cancer, says Padda.

Unlike earlier generation TKIs, the third-generation TKIs select for activity against

Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.

Sukhmani Padda, MD | Authors

Articles

Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer

Exploring Advantages to Third-Generation TKIs in Lung Cancer